Nilotinib (AMN-107)

製品コードS1033

Nilotinib (AMN-107)化学構造

分子量(MW):529.52

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 34860.00
JPY 78020.00

カスタマーフィードバック(5)

  • Ba/F3-p210T315I cells were treated with indicated concentrations of nilotinib with or without PDMP for 24 h. Apoptosis was determined as in A. Data are shown as percentage of sub-G1 for apoptosis in triplicate cultures. *P<0.05.

    FASEB J 2011 25, 3661-3673. Nilotinib (AMN-107) purchased from Selleck.

    Effect of nilotinib on Bcr-Abl kinase activity in ABCB1- and ABCG2- overexpressing CD34+CD38- cells. K562 parental cells and CD34+CD38- subpopulation isolated from K562 cells were treated with nilotinib at 0.01, 0.1 and 1.0 umol/L for 12 h. Equal amount of protein was loaded for western blot analysis as described in the Experimental section. The experiments were repeated at least three times independently, and a representative experiment is shown.

    Molecules 2014 19, 3356-75. Nilotinib (AMN-107) purchased from Selleck.

  •  

    Inhibition of thymidine (a and b) and cytarabine (c and d) uptake with nilotinib. The legend is similar to Fig. 1, except that imatinib was replaced by nilotinib.

    Leukemia Res 2012 36, 1311-1314. Nilotinib (AMN-107) purchased from Selleck.

    Nilotinib up-regulates the ERK survival signal in prostate cancer cells. (B and C) Immunoblot analyses of DU-145 cells (B) or DU-145 cells in comparison with LNCaP and PC-3 cells (C) treated with nilotinib for the expression of phospho-ERK1/2 T202/Y204 and total ERK. Immunoblot for GAPDH is shown as a loading control.

    Urol Oncol 2014 0.1016/j.urolonc.2014.06.001. Nilotinib (AMN-107) purchased from Selleck.

  • Immunohistochemical staining of xenografted DU-145 cells after 21 days of treatment with 75 mg/kg/d of nilotinib for phospho-ERK1/2 T202/Y204 expression. It can be noted that tumors explanted from vehicle-treated mice showed mostly positivity at the tumor periphery, whereas tumors explanted from nilotinib-treated mice showed a more evenly distributed phospho-ERK immunostaining (left panels). Quantification of phospho-ERK-positive DU-145 xenografts explanted after 21 days of treatment. Mean and standard errors of positive cells per high-power field (HPF; x40) from at least 3 tumors are given (right panel).

    Urol Oncol 2014 0.1016/j.urolonc.2014.06.001. Nilotinib (AMN-107) purchased from Selleck.

製品安全説明書

Bcr-Abl阻害剤の選択性比較

生物活性

製品説明 Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.
特性 A selective inhibitor of native and mutant Bcr-Abl.
ターゲット
Bcr-Abl [1]
(Murine myeloid progenitor cells)
<30 nM
体外試験

Nilotinib inhibits proliferation, migration, and actin filament formation, as well as the expression of α-SMA and collagen in activated HSCs. Nilotinib induces apoptosis of HSCs, which is correlated with reduced bcl-2 expression, increases p53 expression, cleavage of PARP, as well as increases expression of PPARγ and TRAIL-R. Nilotinib also induces cell cycle arrest, accompanied by increased expression of p27 and downregulation of cyclin D1. Interestingly, Nilotinib not only inhibits activation of PDGFR, but also TGFRII through Src. Nilotinib significantly inhibits PDGF and TGFβ-simulated phosphorylation of ERK and Akt. Furthermore, PDGF- and TGFβ-activated phosphorylated form(s) of Abl in human HSCs are inhibited by Nilotinib. [2] Nilotinib inhibits most imatinib-resistant Bcr-Abl mutations, except for T315I. [3] Nilotinib inhibits PDGF-DD-mediated ERK1/2 activation, basal and PDGF-DD-mediated activation of PDGFRβ and Akt, and schwannoma proliferation. Nilotinib is more potent than imatinib, exerting its maximal inhibitory effect at concentrations lower than steady-state trough plasma levels. [4] Nilotinib also significantly reduces the expression levels of the genes for TGF-β1 and platelet-derived growth factor (PDGF). Nilotinib treatment also significantly inhibits the PDGF-induced proliferation of lung fibroblasts. [5] Nilotinib inhibits the proliferation of Ba/F3 cells expressing p210- and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values ≤12 nM. [6]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHHTWM2OD1yLkCwNFE1PCEQvF2= MnSxV2FPT0WU
KU812 M1T0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\uPWlEPTB;MD6wNFI1QCEQvF2= MkT5V2FPT0WU
EM-2 NWi5NodXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEC0NUDPxE1? MV\TRW5ITVJ?
LAMA-84 MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO5dFZKSzVyPUCuNFA1QSEQvF2= NF\JOnJUSU6JRWK=
MEG-01 NFXJXGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;UUnBjUUN3ME2wMlAxQDJ6IN88US=> MYTTRW5ITVJ?
BV-173 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe3fGlKSzVyPUCuNFExQDlizszN NGewXVJUSU6JRWK=
KASUMI-1 NF:3eVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfKTWM2OD1yLkCyOFE{KM7:TR?= NHjMOXZUSU6JRWK=
NB7 M4nGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3NRlR2UUN3ME2wMlE{PDN7IN88US=> NH3kNZhUSU6JRWK=
BHT-101 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LMUWlEPTB;MD62OFI3OyEQvF2= MYHTRW5ITVJ?
CGTH-W-1 NF\YfJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfrTWM2OD1yLk[0PFch|ryP MWnTRW5ITVJ?
HMV-II MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\ESmlEPTB;MD63OFg4PCEQvF2= MXnTRW5ITVJ?
NKM-1 NELIWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXHfoZwUUN3ME2wMlkxOTVizszN MorkV2FPT0WU
LB2241-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nGcWlEPTB;MT6wNlIzQCEQvF2= M1q3fHNCVkeHUh?=
NCI-H1703 NGXw[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[3XGlEPTB;MT6xPFg4KM7:TR?= NVWzR4xSW0GQR1XS
BE-13 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFwMke0NVYh|ryP NEXiXG1USU6JRWK=
ACN MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXzVJZKSzVyPUGuOVUxPzdizszN NHPD[VVUSU6JRWK=
A204 M{\4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7BSHdKSzVyPUGuOVczODVizszN Ml;YV2FPT0WU
HOP-62 NWnOc3d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF76UWlKSzVyPUGuPFIxPzdizszN NFLTNGlUSU6JRWK=
H9 NH7VR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlGzTWM2OD1{LkezO|k{KM7:TR?= MVvTRW5ITVJ?
HCC1806 Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJwN{SzNlch|ryP MWjTRW5ITVJ?
NOS-1 MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV76dGxXUUN3ME2yMlg4OTB{IN88US=> M2PUbHNCVkeHUh?=
RS4-11 NFS2VmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwOUC2NlMh|ryP NV3DR5VEW0GQR1XS
JAR M1vuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H1SWlEPTB;Mj65NlA5PCEQvF2= NXvKVG5nW0GQR1XS
T98G MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH20e4FKSzVyPUOuNFE{OTNizszN NFnqVmdUSU6JRWK=
NCI-SNU-1 NVHEXXVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjyZ|hPUUN3ME2zMlQxODl{IN88US=> NVrJZoNzW0GQR1XS
SK-MEL-1 NVLVd5QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojGTWM2OD1|LkSzNFI6KM7:TR?= MYjTRW5ITVJ?
L-363 NH3adWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDvTWM2OD1|Lk[xNVA4KM7:TR?= M325Z3NCVkeHUh?=
SW982 Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTNwNkSxOlkh|ryP NVztXIhCW0GQR1XS
HT-1080 NWfzPFVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrBTWM2OD1|LkmxO|c2KM7:TR?= M4LJ[HNCVkeHUh?=
G-402 MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGiyWopKSzVyPUSuN|EzODNizszN NUfrNpRPW0GQR1XS
HOS NYjuZWFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf5VYpKSzVyPUSuPFAzQDJizszN MnjNV2FPT0WU
SK-NEP-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTRwOEOxPVEh|ryP NVj5b2FFW0GQR1XS
HAL-01 M33pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTRwOEiyOFIh|ryP MVXTRW5ITVJ?
SBC-1 MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{GySGlEPTB;ND65NFkxPyEQvF2= MULTRW5ITVJ?
CTV-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvVTWM2OD13LkS4PVM5KM7:TR?= MXfTRW5ITVJ?
LCLC-103H MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf1S4JVUUN3ME21Mlc4PDdzIN88US=> M{TnOXNCVkeHUh?=
RVH-421 M2jMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTVwN{e1N|Yh|ryP NIDnS4xUSU6JRWK=
K-562 NETDXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTVwOUCzOkDPxE1? MkDyV2FPT0WU
CAL-33 NEnrc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DvZ2lEPTB;Nj6zNVM2QSEQvF2= MX\TRW5ITVJ?
MDA-MB-361 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;JcoR4UUN3ME22MlM{Pjl7IN88US=> NVTEU|ZLW0GQR1XS
IGROV-1 M2C5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTZwNEexPVEh|ryP MoTnV2FPT0WU
NY MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLJTWM2OD14LkWzOVk6KM7:TR?= MkPmV2FPT0WU
Ramos-2G6-4C10 NX:4VIlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJTWM2OD14Lk[2PVMyKM7:TR?= NVv5foVQW0GQR1XS
HuO9 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTZwN{O5OlQh|ryP NHG0S3NUSU6JRWK=
MS-1 NYLZU29VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnwUWhlUUN3ME23MlEyQTV|IN88US=> MYDTRW5ITVJ?
RPMI-8226 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTdwMkiyPFch|ryP M2PoUXNCVkeHUh?=
HDLM-2 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTdwNECxOFkh|ryP MoW2V2FPT0WU
D-566MG NGj4[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3iO|dbUUN3ME23MlQ4OTV3IN88US=> M165O3NCVkeHUh?=
SK-MEL-24 NH72VIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTdwNkOzPVIh|ryP MnHIV2FPT0WU
COLO-679 NVv0V4RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV32ZnhiUUN3ME23Mlk5PjdzIN88US=> MV\TRW5ITVJ?
EW-13 Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDnWIJKSzVyPUiuN|IxPTRizszN MlewV2FPT0WU
A388 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn2Z|BnUUN3ME24MlM5PDhzIN88US=> NUHjPIFOW0GQR1XS
UM-UC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRThwNEO5OVYh|ryP MVzTRW5ITVJ?
NUGC-3 M{SxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrhbY5KSzVyPUiuOVM2QDJizszN NUG0NXVxW0GQR1XS
COLO-668 NGe1e2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLaOYpNUUN3ME24MlU6PDlzIN88US=> MVXTRW5ITVJ?
MOLT-4 MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRThwNkKzOVMh|ryP MVzTRW5ITVJ?
D-423MG M2S4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljvTWM2OD16LkizO|U3KM7:TR?= NEnYSXNUSU6JRWK=
CTB-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\2OWhjUUN3ME24Mlg4OTJ6IN88US=> Mlj0V2FPT0WU
BCPAP MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD1RZpKSzVyPUmuNFI2PjJizszN MVvTRW5ITVJ?
GCT NYP2bY54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjHVo1KSzVyPUmuNFk5OzFizszN NFXabHFUSU6JRWK=
ACHN NFe2OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTlwMkO2N|Ih|ryP NIXSfYdUSU6JRWK=
KYSE-520 NVjhVnFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjTcpBKSzVyPUmuN|M1QDJizszN MWrTRW5ITVJ?
LB771-HNC NIXwb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOwbG1DUUN3ME25Mlc3PDl5IN88US=> MXHTRW5ITVJ?
MLMA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXidXJ4UUN3ME2xNE4xOTN{IN88US=> NV3UeJlOW0GQR1XS
HEC-1 NWXNcJRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETHdJpKSzVyPUGwMlI5ODRizszN NFe2[oJUSU6JRWK=
HL-60 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDMTWM2OD1zMD62PFU{KM7:TR?= NFH2eoJUSU6JRWK=
A101D NHvMPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml34TWM2OD1zMD64PVI{KM7:TR?= M2jqV3NCVkeHUh?=
A2058 NXXNU244T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jIS2lEPTB;MUCuPVI1PSEQvF2= MV;TRW5ITVJ?
KARPAS-45 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLwXHRxUUN3ME2xNU4xPjN3IN88US=> NWi4NXNoW0GQR1XS
697 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LwUWlEPTB;MUGuNlExOSEQvF2= NUTWT3RJW0GQR1XS
NCI-N87 NX[xSVZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jtXGlEPTB;MUGuO|c{OSEQvF2= NFLLWXZUSU6JRWK=
DSH1 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjNNGxKSzVyPUGxMlc6PTNizszN MVTTRW5ITVJ?
HLE MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFzLki4N|kh|ryP MVzTRW5ITVJ?
NCI-H720 NGrrPYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H5[GlEPTB;MUKuOlgxOSEQvF2= MWPTRW5ITVJ?
EW-3 M4PWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX6VIRKSzVyPUGyMlk{ODdizszN M2nQPHNCVkeHUh?=
AGS MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTF|LkCzOVEh|ryP NUPG[YY3W0GQR1XS
ES5 NE\aXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF|LkC1NVIh|ryP M4TETnNCVkeHUh?=
DB M{[yVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XUemlEPTB;MUOuN|I2PiEQvF2= M1j0fnNCVkeHUh?=
A4-Fuk NHvofmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF|LkSxNFIh|ryP MlG2V2FPT0WU
A427 NXrHNmRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXzTWM2OD1zMz60PVczKM7:TR?= NFWzcXFUSU6JRWK=
MN-60 MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nwVGlEPTB;MUOuOVg1OyEQvF2= NF3MN|hUSU6JRWK=
HCC2218 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzFR3l5UUN3ME2xN{42QDV4IN88US=> MYTTRW5ITVJ?
MV-4-11 NXG1foptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF|LkixN|ch|ryP NXLKcXF1W0GQR1XS
GI-1 MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\M[nlKSzVyPUG0MlEyQDRizszN MX\TRW5ITVJ?
JVM-3 NGGzc|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG4TWM2OD1zND6yOlU3KM7:TR?= M1Hnd3NCVkeHUh?=
NCI-H2029 NWfESmZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLWTWM2OD1zND6yO|I4KM7:TR?= NV[0OnM4W0GQR1XS
TE-12 NXy3OGhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF2Lk[wOFYh|ryP NXi0cXp7W0GQR1XS
WM-115 M2DCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDJSldSUUN3ME2xOU42Pjh|IN88US=> M2rWdnNCVkeHUh?=
BB65-RCC M3juO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzNTWM2OD1zNj6wNlQyKM7:TR?= M2eyPHNCVkeHUh?=
NCI-H1693 NEXZRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK5PZlKSzVyPUG2MlM5ODJizszN NXWzTG8{W0GQR1XS
KARPAS-299 NHnwPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTwSYRmUUN3ME2xOk43OjB|IN88US=> NIHseG5USU6JRWK=
UACC-257 Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3VNItNUUN3ME2xO{4xPTh{IN88US=> M1f2[3NCVkeHUh?=
RKO NU\vNW9wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjhSpF6UUN3ME2xO{43PDN|IN88US=> NYPD[GJ7W0GQR1XS
HT-29 M4P5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn0[WhKSzVyPUG3Mlc5QDlizszN MYrTRW5ITVJ?
ES7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHiVHlKSzVyPUG4MlEyOjJizszN NIfxSFFUSU6JRWK=
DEL NETWVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3XSVN1UUN3ME2xPE4{OTd{IN88US=> NH:5UmRUSU6JRWK=
BT-549 NULCNmhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3UTWM2OD1zOD60NFkzKM7:TR?= NEHKOm5USU6JRWK=
NCI-H1755 NXvv[HNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn3dodXUUN3ME2xPE42PzJ|IN88US=> M1v1TnNCVkeHUh?=
HCE-T NXK2XWI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF6LkizOFEh|ryP NU\NbVg5W0GQR1XS
LU-139 MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H0N2lEPTB;MUmuNFQ2QCEQvF2= MlTCV2FPT0WU
ECC10 NFTyWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF7LkK0O|Uh|ryP NH:0bWpUSU6JRWK=
769-P NXy3coE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfqdnUzUUN3ME2xPU43OzN3IN88US=> NUL6[m94W0GQR1XS
BALL-1 MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF7Lk[3O|Uh|ryP MV3TRW5ITVJ?
LXF-289 M2G2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF7Lki5O|kh|ryP Mlz2V2FPT0WU
TYK-nu NFnLWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfkPYdpUUN3ME2xPU46OzF3IN88US=> NWL4[mdWW0GQR1XS
NCI-H630 MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF7LkmzO|gh|ryP NEHDNmNUSU6JRWK=
EW-18 M{nCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXDT49sUUN3ME2yNE4{QDB{IN88US=> NGTN[4JUSU6JRWK=
KYSE-150 NWTHNJBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\hNWhsUUN3ME2yNE44ODR5IN88US=> MkP4V2FPT0WU
LOXIMVI MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJyLke1PFYh|ryP NXzvd|EzW0GQR1XS
HuP-T3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTuTWM2OD1{MT6wPFUzKM7:TR?= MlvsV2FPT0WU
MFE-280 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;nRmlEPTB;MkGuOVY4QSEQvF2= M2PTR3NCVkeHUh?=
SK-OV-3 NIr3VnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli4TWM2OD1{MT64OFA5KM7:TR?= NGfPRXJUSU6JRWK=
QIMR-WIL NID3dZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrWfldqUUN3ME2yNk4xPDd6IN88US=> MWfTRW5ITVJ?
NCI-H69 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHhZmJ6UUN3ME2yNk41Ojl7IN88US=> M2HtfnNCVkeHUh?=
TE-5 NFG0R5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXqTWM2OD1{Mj60PVY2KM7:TR?= Mnq1V2FPT0WU
NCI-H1993 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJ{LkS5O|Eh|ryP NHPaOo5USU6JRWK=
NCI-H1092 M4\jdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm1dJY6UUN3ME2yN{4zQDR|IN88US=> M4jIVXNCVkeHUh?=
RH-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\O[XpKSzVyPUKzMlU{PTdizszN NFi3XJhUSU6JRWK=
DBTRG-05MG NX\aOWgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTWTWM2OD1{Mz64OFczKM7:TR?= M1LqSXNCVkeHUh?=
Mo-T NXrsRlc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH3XZdKSzVyPUKzMlkh|ryP MXXTRW5ITVJ?
HD-MY-Z NXzDRpZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MomzTWM2OD1{ND6yN|YzKM7:TR?= Mo\xV2FPT0WU
NCI-H2342 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzCPIJEUUN3ME2yOE43PzZ5IN88US=> M1LhcnNCVkeHUh?=
C32 NYDpdVBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDJTWM2OD1{ND65OVc3KM7:TR?= NF;admFUSU6JRWK=
HTC-C3 M3nLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrqVlJvUUN3ME2yOU4{PTd5IN88US=> NUe3fHpuW0GQR1XS
NCI-H358 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ3LkO5OFMh|ryP MYjTRW5ITVJ?
CAL-85-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJ3LkS1O|ch|ryP NInLcGNUSU6JRWK=
HT-1197 M1XiN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGruW49KSzVyPUK1MlU{OTlizszN NWDLO|BHW0GQR1XS
A172 MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljOTWM2OD1{NT63NVM3KM7:TR?= M3vJVnNCVkeHUh?=
SW1573 MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PXZmlEPTB;MkWuO|c5PSEQvF2= M4P2TXNCVkeHUh?=
EW-24 NHTXZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3ZO|ZKSzVyPUK1Mlk3OiEQvF2= MYrTRW5ITVJ?
SK-MEL-2 NH3WTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHxNXlKSzVyPUK2MlA{OTJizszN MWTTRW5ITVJ?
LU-65 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfSXm5rUUN3ME2yOk4xPDV{IN88US=> Mnq2V2FPT0WU
KMOE-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTJ4LkC5NVUh|ryP M{f5ZnNCVkeHUh?=
H-EMC-SS M1;0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LqT2lEPTB;Mk[uOFEyPCEQvF2= M1jGSXNCVkeHUh?=
H4 M1nJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO4epU3UUN3ME2yOk41OjR|IN88US=> MU\TRW5ITVJ?
DU-4475 M{T4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjkOIs4UUN3ME2yO{4yQDd{IN88US=> NF\tcotUSU6JRWK=
HCT-116 M1vhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT5TWM2OD1{Nz60N|Q6KM7:TR?= MUPTRW5ITVJ?
MSTO-211H MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\UTWM2OD1{Nz62NlU2KM7:TR?= MoO0V2FPT0WU
NCI-H292 NGq5PZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ5Lkm2NVch|ryP NXfsTG5HW0GQR1XS
NCI-H446 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ6LkKxNFUh|ryP MUnTRW5ITVJ?
NCI-H2009 NI\ONGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjhT|VKSzVyPUK5MlE1OzFizszN NI\nTYJUSU6JRWK=
MHH-ES-1 NGDrSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJ7LkO2PFUh|ryP NHvKbZhUSU6JRWK=
TI-73 MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz2XVJKSzVyPUK5MlQxODFizszN M{DvNXNCVkeHUh?=
NCI-H2228 M4TmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTKTWM2OD1{OT60OVgh|ryP MVTTRW5ITVJ?
MHH-PREB-1 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED2SmVKSzVyPUK5MlU2ODVizszN NEPpVXdUSU6JRWK=
ChaGo-K-1 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TTWWlEPTB;MkmuOlA6PyEQvF2= MlTiV2FPT0WU
KY821 NFKxUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP4NJlKSzVyPUK5MlY1OzNizszN Ml7rV2FPT0WU
NCI-H209 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIOzT2xKSzVyPUK5Mlg{PjZizszN M4DlU3NCVkeHUh?=
NBsusSR MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ7Lkm5NFQh|ryP NVLQTFE4W0GQR1XS
NCI-H1304 NVfPS|RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDNTWM2OD1|MD61O|E3KM7:TR?= NGfHR2RUSU6JRWK=
NB14 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXKT|JnUUN3ME2zNU4xPDR4IN88US=> NV\jcG9VW0GQR1XS
HCC1419 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTNzLkK0JO69VQ>? NYj1dIZKW0GQR1XS
KG-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNzLke0Nlkh|ryP NE\penRUSU6JRWK=
A2780 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNzLkizOVgh|ryP MVnTRW5ITVJ?
NCI-H28 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M160fWlEPTB;M{GuPVg3OSEQvF2= MmHrV2FPT0WU
C2BBe1 MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTN{LkK2N|Qh|ryP NV2yZ3pmW0GQR1XS
VA-ES-BJ MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTmTWM2OD1|Mj6zNUDPxE1? NEL4d|RUSU6JRWK=
SBC-5 NYHUeWJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTN{Lki1NVEh|ryP NGTNWGpUSU6JRWK=
OVCAR-4 NHuxRmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN|LkS4OFgh|ryP NEe4UYVUSU6JRWK=
COR-L88 NFqyPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HCUWlEPTB;M{SuNFc1OSEQvF2= NFX6cI1USU6JRWK=
SW954 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTN2LkC3OVIh|ryP MYTTRW5ITVJ?
COLO-684 M3nzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;TOWlEPTB;M{SuN|QxPCEQvF2= NVHldWRjW0GQR1XS
HCC70 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmriTWM2OD1|ND65OVE1KM7:TR?= NUOyT|VRW0GQR1XS
NCI-H1770 NEjoZ|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vYSmlEPTB;M{SuPVYyKM7:TR?= NWnrT4hYW0GQR1XS
NCI-H1666 NY\sdWZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7teYlMUUN3ME2zOU45OjV|IN88US=> MkDrV2FPT0WU
YH-13 NFTUXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVraTlg2UUN3ME2zOU46OiEQvF2= NYL6WpJpW0GQR1XS
DJM-1 NHLrPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGe0c45KSzVyPUO2MlgxPDlizszN M2CyUHNCVkeHUh?=
KNS-62 M3zId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXFTWM2OD1|Nj65OFM5KM7:TR?= MmC3V2FPT0WU
SK-MEL-30 NYfCTFRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2mxfWlEPTB;M{euPFc{PyEQvF2= MlnHV2FPT0WU
SJRH30 M4LIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO2TWM2OD1|OD63N|QyKM7:TR?= M1\rUXNCVkeHUh?=
GP5d NIfjS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojVTWM2OD1|OD64OlU{KM7:TR?= MWTTRW5ITVJ?
SW1116 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTN7LkK4NFUh|ryP MXzTRW5ITVJ?
COLO-800 MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfrS|NKSzVyPUO5MlM3OzhizszN NXm5SnAxW0GQR1XS
RD NGXkRlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTJ[VFKSzVyPUO5MlUzPThizszN MkDWV2FPT0WU
NCI-SNU-5 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTN7Lk[5NVYh|ryP M1i3UHNCVkeHUh?=
HuO-3N1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTRyLkGwPEDPxE1? MnH6V2FPT0WU
SK-UT-1 NWDzT2RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLyTWM2OD12MD61Olc1KM7:TR?= Mm[4V2FPT0WU
SK-MEL-3 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkO4TWM2OD12MD61PVMzKM7:TR?= NHixeppUSU6JRWK=
SK-MEL-28 NHvCcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3TcWVKSzVyPUSwMlY1OzVizszN M{O1c3NCVkeHUh?=
SCC-4 NWTweJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDZdVJKSzVyPUSxMlIyOzdizszN MnTQV2FPT0WU
no-11 NHvwTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO1dHlUUUN3ME20NU44OzV2IN88US=> MmPBV2FPT0WU
HT-144 NWGwWVB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnTSY5KSzVyPUSyMlA2PjdizszN NFPqdlJUSU6JRWK=
MFM-223 NGDFNHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M335[GlEPTB;NEKuOFAzKM7:TR?= NITiSZZUSU6JRWK=
ONS-76 NYWyV2dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTmeJpGUUN3ME20Nk45ODF6IN88US=> NEfTNZZUSU6JRWK=
ES8 NVHHOW5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrqZ4hKSzVyPUSzMlM3QThizszN MmjYV2FPT0WU
T-24 NUSxd2JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37JUWlEPTB;NEOuOFM3QSEQvF2= M1zuSnNCVkeHUh?=
GAMG NX3wOmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LEV2lEPTB;NEOuOFUyPyEQvF2= NWLoWVk2W0GQR1XS
LU-135 NYCzZWEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR2LkC5NlMh|ryP MYXTRW5ITVJ?
HCC1187 M1\oTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG5R2tKSzVyPUS0MlgzPjJizszN M2W5VHNCVkeHUh?=
TE-1 NVO4bZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELhPYpKSzVyPUS1MlE3PTRizszN MnG5V2FPT0WU
J-RT3-T3-5 NFTvR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX6yUY8xUUN3ME20OU41OzF3IN88US=> MYDTRW5ITVJ?
GI-ME-N NYfOXWJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\qVFJKSzVyPUS1Mlg6PTJizszN NUfFRmpQW0GQR1XS
D-392MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4OzXmlEPTB;NEWuPVI2PiEQvF2= NXHxNIRRW0GQR1XS
KALS-1 NVjveG5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTR4LkeyOVch|ryP NW[0OlN{W0GQR1XS
MMAC-SF MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH4ZYhKSzVyPUS2Mlk6PTJizszN MVLTRW5ITVJ?
HSC-3 NFTLO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR5LkO2NFgh|ryP M4[1R3NCVkeHUh?=
KM-H2 NYf4d5JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIezRWlKSzVyPUS3MlYxODdizszN NF[weItUSU6JRWK=
LoVo MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H4TGlEPTB;NEiuNVAxOiEQvF2= MnvEV2FPT0WU
NCI-H510A M4nyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTR6LkG4O|Eh|ryP M3HRWHNCVkeHUh?=
EW-11 NIH3fIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTR6LkKzOFgh|ryP NX\R[GFmW0GQR1XS
HCC2998 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HncGlEPTB;NEiuOlI{PiEQvF2= MWjTRW5ITVJ?
J82 NXPQdlhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGwSmtHUUN3ME20PE44OjR{IN88US=> NF3KV4ZUSU6JRWK=
ML-2 M1[5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW3TWM2OD12OT60OlA2KM7:TR?= Ml7BV2FPT0WU
NCI-H2030 M4LKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\mTWM2OD12OT63NVE4KM7:TR?= NVvv[W9pW0GQR1XS
NCI-H1792 M2C4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1mwOmlEPTB;NEmuPFUyQCEQvF2= MVnTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Nilotinib reduces collagen deposition and α-SMA expression in CCl4 and BDL-induced fibrosis. Nilotinib could induce HSC undergoing apoptosis, which is correlated with downregulation of bcl-2. [2] Nilotinib attenuates the extent of lung injury and fibrosis. Nilotinib therapy significantly reduces the levels of hydroxyproline on days 14 and 21, which is accompanied by decreased expression levels of transforming growth factor (TGF)-β1 and PDGFRβ. [5] AMN107 prolongs survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolongs survival in imatinib-resistant CML mouse models. [6]

お薦めの試験操作(参考用のみ)

細胞試験: [4]
+ 展開
  • 細胞株: Human primary Schwann and schwannoma cells
  • 濃度: 1-10 μM
  • 反応時間: 72 hours
  • 実験の流れ: Human primary Schwann and schwannoma cells are seeded on precoated 96-well plates. Nilotinib is added 40 minutes before stimulation with 100 ng/mL PDGF-DD, and cells are cultured for 72 hours (3 days). Because the half-life of Nilotinib is 18 hours, one-half of the originally added concentrations are added freshly every day. In addition to DAPI staining and determination of the total cell number, the more sensitive and accurate BrdU incorporation method is used to detect proliferating cells. Total cell amount (DAPI) and number of dividing cells (BrdU-positive) are blindly counted using an inverted fluorescent microscope and 200 × magnification. All cells in every well are counted. The total cell number per well differed between various cell batches and is 100–300 cells/well.
    (参考用のみ)
動物試験:[6]
+ 展開
  • 動物モデル: Systemic 32D Bcr-Abl leukemia model in Female BALB/c mice, Bioluminescent Bcr-Abl model of CML in Female NOD-SCID mice and Bone marrow transplant Bcr-Abl model of CML in syngeneic Balb/c recipient mice
  • 製剤: 10% NMP-90% PEG300, PEG300
  • 投薬量: 75 mg/kg, 100 mg/kg
  • 投与方法: Oral administration
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 27 mg/mL (50.98 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
3mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 529.52
化学式

C28H22F3N7O

CAS No. 641571-10-0
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03874858 Not yet recruiting Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 1 2019 Phase 2
NCT03874858 Not yet recruiting Chronic Myeloid Leukemia Novartis Pharmaceuticals|Novartis April 1 2019 Phase 2
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3
NCT03784014 Not yet recruiting Soft Tissue Sarcoma Institut National de la Santé Et de la Recherche Médicale France|Commissariat A L''energie Atomique|Institut Bergonié|Plateforme labellisée Inca – Institut Bergonié Bordeaux|Plateforme labellisée Inca – Hôpital Européen Georges Pompidou Paris|CIC-EC 1401/EUCLID March 2019 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use AMN-107 for in vivo studies in mice, can you give me some suggestions about the in vivo formulation?

  • 回答:

    For in vivo study, we recommend to use 4% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 3mg/ml.

Bcr-Ablシグナル伝達経路

Bcr-Abl Inhibitors with Unique Features

相関Bcr-Abl製品

Tags: Nilotinib (AMN-107)を買う | Nilotinib (AMN-107) ic50 | Nilotinib (AMN-107)供給者 | Nilotinib (AMN-107)を購入する | Nilotinib (AMN-107)費用 | Nilotinib (AMN-107)生産者 | オーダーNilotinib (AMN-107) | Nilotinib (AMN-107)化学構造 | Nilotinib (AMN-107)分子量 | Nilotinib (AMN-107)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID